Stuart

Stuart Therapeutics is a clinical-stage biopharmaceutical company developing a new class of therapeutic agents for ophthalmic diseases. The company's core technology, the PolyCol platform, consists of synthesized collagen mimetic peptides designed to repair and restore the extracellular matrix in diseased ocular tissues. Their lead drug candidate, ST-100, is being evaluated in Phase 3 clinical trials for the treatment of Dry Eye Disease, aiming to provide faster onset of action and improved corneal healing compared to current standards of care. Stuart's pipeline also includes programs targeting glaucoma, Fuchs' corneal dystrophy, and chronic corneal wounds. By focusing on the structural integrity of the eye's tissues, the company seeks to address the underlying causes of vision loss and discomfort. The platform's mechanism of action offers a differentiated approach from existing anti-inflammatory treatments.